ESC Heart Failure, 2021 Aims Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We aimed to evaluate the synergistic effects of these two medications.
Ying‐Hsiang Lee +9 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source
Declining risk of sudden death in heart failure [PDF]
, 2017 No abstract ...
Jhund, Pardeep S. +2 more
core +1 more source
Clinical and Experimental Hypertension, 2019 Background: Sacubitril (SAC), a neprilysin inhibitor prevent degradation of neprilysin and activate cGMP signaling pathways leading to rise in blood volume concurrent to blood pressure by means of vasoactive peptides, adrenomedullin, and bradykinin ...
Mohd Imran +5 more
doaj +1 more source
ESC Heart FailureThis study sought to assess the effect of treatment of sacubitril/valsartan (S/V) on improving cardiac function and reversing cardiac remodelling in patients with acute coronary syndrome (ACS) complicated with heart failure with reduced ejection fraction
Henan Liu +12 more
semanticscholar +1 more source
Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats
ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén +16 more
wiley +1 more source
Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. [PDF]
, 2017 Importance: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ( guided therapy ) with inconsistent ...
Adams, Kirkwood F. +15 more
core +3 more sources
Sacubitril with valsartan, a modern pharmacotherapy in heart failure - a literature review
Quality in SportIntroduction and purpose: Heart failure is one of the most common cardiovascular diseases worldwide. It is an important factor leading to a reduced, health-related quality of life (HRQoL) not only because of its various symptoms but also due to loss of ...
Bartosz Sadłowski +9 more
doaj +1 more source
Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials [PDF]
, 2022 Hong-Xing Wu +4 more
openalex +1 more source
Molecular Implications of natriuretic peptides in the protection from hypertension and target organ damage development [PDF]
, 2019 The pathogenesis of hypertension, as a multifactorial trait, is complex. High blood pressure levels, in turn, concur with the development of cardiovascular damage.
Forte, Maurizio +3 more
core +1 more source